ERD-12310A , CAS No.E1448525

CAS: E1448525 Cat. No.: E1448525 Formule: C51H56N4O6 Poids moléculaire: 821.01
DISPONIBLE À COMMANDE
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
★
Taille
USA
Allemagne (EU)*
Prix
Qté
1mg
E1448525-1mg
Sur commande · 8–12 semaines
Enter a quantity for the sizes you want to add.

Vue d’ensemble

ERD-12310A is a PROTAC targeting Estrogen Receptor α ( ERα ) with a ED 50 value of 47 pM. ERD-12310A has oral activity. ERD-12310A is composed of PROTAC target protein ligand ER ligand-4 (red part), E3 ligase ligand (S)-Deoxy-thalidomide (blue part).

Spécifications

Conditions de stockage de stockage
Store at -20°C
Expédié en
Ice chest + Ice pads
Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.
Noms et identifiants
Poids moléculaire
821.01

Données avancées

Certificats (CoA, COO, BSE/TSE et tableau d'analyse)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Calculateurs de solution
Avis

Avis des clients

Application Protocols

No tested application protocols are provided in the Product Data for ERD-12310A.

General protocol guidance for screening compounds (research use only):

  • Stock preparation: Dissolve in anhydrous DMSO to 10–50 mM. Vortex and, if needed, sonicate briefly. Filter through 0.22 μm PTFE if particulate persists and the compound is not adsorptive.
  • Aliquoting: Dispense into low-binding microtubes or assay plates to create single-use aliquots; avoid repeated freeze–thaw cycles.
  • Assay dilution: Add stock to assay buffer under mixing to reach final DMSO ≤0.1–1% v/v, depending on assay tolerance. Include vehicle controls at matched DMSO level.
  • Controls: Incorporate detergent controls (e.g., 0.01–0.05% non-ionic surfactant) for aggregation-sensitive targets and redox/fluorescence interference controls where relevant.
  • Data QC: Inspect wells for precipitation/cloudiness, monitor edge effects in plates, and confirm concentrations by back-calculation from acoustic/pintool transfer logs.

Any item-specific, validated protocols: Not specified for this item; refer to CoA/Spec Sheet or internal method files.

Biological Roles

No target or pathway information is provided for ERD-12310A. As supplied, it is a research-only small-molecule library member with unspecified biological activity.

General considerations for library compounds in biology (no clinical claims):

  • Use in hypothesis generation: Screen against purified enzymes, receptors, transporters, or in cell-based phenotypic assays to identify modulators of biological pathways.
  • Follow-up characterization: If activity is observed, characterize mechanism (competitive, allosteric, covalent vs. reversible), time dependence, and selectivity across isoforms or off-target panels.
  • Develop structure–activity relationships (SAR): Acquire close analogs and use cheminformatics to rationalize potency changes; confirm identity and purity of each lot to avoid confounding results.
  • Liability assessment: Evaluate aggregation, redox activity, fluorescence interference, and reactivity toward thiols or nucleophiles to rule out assay artifacts.

Important: Without structural and bioactivity data for ERD-12310A, no specific biological role can be assigned. Treat any observed effects as preliminary until confirmed by orthogonal assays and appropriate controls.

Buffer Applications

This product is not a buffering reagent, and no acid/base properties are provided. Therefore, buffer formulation guidance is generally not applicable.

Practical note for assay buffers (general):

  • When using ERD-12310A in biochemical assays, choose a buffer system compatible with the biological target (e.g., HEPES pH 7.4, PBS pH 7.2–7.4, Tris pH 7.5–8.0) and confirm that the compound remains in solution at the final cosolvent percentage.
  • To minimize precipitation: Add compound stock (in DMSO or other solvent) last, under vigorous mixing, and avoid sudden dilution into cold buffers if solubility is marginal.

Item-specific buffer capacity/pH data: Not specified for this item; refer to CoA/Spec Sheet.

Green Alternatives

In the absence of compound-specific solvent constraints, consider greener solvent strategies for handling ERD-12310A while preserving assay compatibility.

  • Preferred where feasible:
    • Water with benign co-solvents at low percentages (EtOH, i-PrOH) if the compound remains soluble and stable.
    • DMSO is broadly accepted and relatively benign compared to dipolar aprotics like DMF/NMP for lab-scale use; keep final assay DMSO ≤1% v/v.
  • To minimize environmental impact:
    • Avoid chlorinated solvents for routine dissolution or cleaning unless strictly necessary.
    • Replace DMF/NMP with Cyrene, propylene carbonate, or ethyl lactate in synthetic or preparative contexts when compatible (literature-based green alternatives).

Comparison (general; literature):

  • DMSO: Low volatility, good safety profile; may interfere with some enzymes at higher percentages.
  • Ethanol/i-PrOH: Renewable sources available; higher volatility; limited solvating power for very lipophilic compounds.
  • Cyrene/ethyl lactate: Greener metrics; viscosity or hydrolytic stability can be limiting.

Best practice: Validate ERD-12310A solubility in the greener choice at the intended working concentration, and document any impact on assay signal or background.

Pharmaceutical Uses

No pharmacopeial status, excipient role, or formulation use is provided for ERD-12310A. It is supplied strictly for research use only and is not intended for human or veterinary use, diagnostics, or clinical applications.

General R&D context for library compounds (non-clinical):

  • Early discovery: Employed in hit identification and preliminary SAR prior to any consideration of developability.
  • Pre-formulation research: If activity warrants, basic solubility and stability assessments (pH solubility profile, thermodynamic vs. kinetic solubility, photostability) can inform future medicinal chemistry optimization.
  • Not for GMP manufacturing or as an excipient. There is no established dosage form, route, or pharmacopeial monograph for this item.

Item-specific pharmaceutical information: Not specified for this item; refer to CoA/Spec Sheet.

Physical Properties

Item-specific physicochemical data are not provided in the Product Data and should be confirmed on the CoA/Spec Sheet before use.

  • Melting point (MP): Not specified for this item; refer to CoA/Spec Sheet.
  • Boiling point (BP): Not specified for this item; refer to CoA/Spec Sheet.
  • Density: Not specified for this item; refer to CoA/Spec Sheet.
  • Solubility: Not specified for this item; refer to CoA/Spec Sheet.
  • LogP/logD: Not specified for this item; refer to CoA/Spec Sheet.
  • pKa(s): Not specified for this item; refer to CoA/Spec Sheet.
  • Refractive index: Not applicable/unknown for solids; otherwise, not specified for this item; refer to CoA/Spec Sheet.

General guidance for small-molecule library members (literature/practice):

  • Many library compounds are solids at ambient temperature. If supplied as dry film or powder, determine solubility empirically using a stepwise approach: DMSO (first-line), then DMF, ethanol or methanol, and finally aqueous buffers with co-solvent.
  • Typical stock solutions: 10–50 mM in anhydrous DMSO (literature). Verify actual solubility and stability before committing to assay plates.
  • If ionizable groups are present, solubility may improve by adjusting pH (±1–2 units around predicted pKa) in aqueous-organic mixtures (e.g., 10–50% DMSO or MeOH in buffer). Avoid strong base/acid unless compatible with the compound.
  • Hygroscopicity and photolability vary; handle rapidly at room temperature and minimize light exposure until properties are known (precautionary best practice).
Quality and Grades

Item-specific grade and purity are not listed in the Product Data.

  • Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.

Interpretation and expectations (general for screening library members):

  • Library compounds are commonly supplied at defined purity thresholds (e.g., ≥90–98% by HPLC/UPLC) with identity confirmed by LC–MS and/or NMR. Verify the specific acceptance criteria on the CoA.
  • Low UV background, residual solvent levels, and water content may be reported on the CoA. If your application is LC–MS-driven, request chromatograms and mass spectra to confirm single-component behavior.
  • Batch-to-batch continuity: Library entries may be resynthesized or re-sourced; always match SKU/lot to the corresponding CoA.
  • Impurities/stabilizers: If stabilizers or salt forms are used, they will be noted on the CoA/Spec Sheet. Absent such notation, do not assume the presence or absence of stabilizers.

Practical guidance:

  • For quantitative biology or biophysics, consider in-house verification (orthogonal purity check, e.g., qNMR, HPLC with PDA/MS) prior to SAR or PK profiling.
  • For plate-based screening, confirm solubility and lack of precipitate at working concentrations; document any cosolvent percentages used to reach clarity.
Reaction and Applications

Manufacturer application field is not provided; ERD-12310A is categorized under small molecules/compound libraries and is intended for research use.

Typical applications for library members (general):

  • High-throughput screening (HTS), fragment or diversity screening in biochemical, biophysical (e.g., SPR, DSF), and cell-based assays to identify preliminary actives.
  • Chemical biology: Use as a probe candidate in pathway interrogation, target deconvolution studies, and phenotypic profiling once activity is observed.
  • Orthogonal confirmation: Secondary assays, counter-screens, and PAINS/REOS filtering to validate hits and eliminate assay artifacts.

Practical tips:

  • Stock preparation: Start at 10–50 mM in anhydrous DMSO. Use gentle warming (≤37 °C) and sonication as needed; avoid prolonged heat exposure until stability is known.
  • Plate handling: Minimize freeze–thaw by preparing multiple single-use aliquots. Use acoustic or pintool transfer to maintain concentration accuracy and reduce DMSO carryover.
  • Adsorption mitigation: For sticky compounds, include small amounts of surfactant and use low-binding plastics; pre-rinse tips with compound solution for low-volume transfers.
  • Aggregation control: Include non-ionic detergents at low levels (e.g., 0.01–0.05%) in assays susceptible to colloidal aggregation artifacts; perform detergent-sensitive control assays.

Note: Without structural information, no specific synthetic or named-reaction roles can be assigned to ERD-12310A.

Reaction Conditions

No structure or reactivity data are provided for ERD-12310A; therefore, specific reaction conditions cannot be recommended.

General laboratory considerations for unknown small molecules:

  • Stability testing: Before any transformation, assess stability in common solvents (DMSO, MeOH, ACN) and under mild heating (e.g., 40 °C) and light exposure. Avoid strong acids/bases and oxidants until compatibility is known.
  • Analytical setup: Establish LC–MS and HPLC/UPLC-PDA methods to monitor purity and detect degradation products during any exploratory chemistry.
  • If derivatization or tagging is intended (e.g., to make an affinity probe), first confirm presence of appropriate functional groups via NMR/IR/MS from the CoA or your own characterization.

Expected yields, catalysts, and temperature ranges: Not applicable without structural information.

Safety and Handling

Hazard classification details are not provided in the Product Data; consult the product SDS for authoritative information before handling.

  • GHS classification: Not specified for this item; refer to SDS.
  • Signal word / H-statements / Pictograms: Not specified for this item; refer to SDS.

General laboratory precautions (best practice for unknown small molecules):

  • Wear appropriate PPE: lab coat, safety glasses, and chemical-resistant gloves (e.g., nitrile). Work in a fume hood to avoid inhalation of dusts or vapors.
  • Avoid ingestion, inhalation, and skin or eye contact. Prevent aerosolization during weighing and solution preparation.
  • Storage incompatibilities (general): Separate from strong oxidizers, strong acids/bases, and reducing agents until compatibility is known. Keep container tightly closed and desiccated.
  • Spill/first aid overview (defer to SDS for specifics):
    • Skin/eye contact: Rinse with copious water for at least 15 minutes; remove contaminated clothing. Seek medical attention if irritation persists.
    • Inhalation: Move to fresh air; seek medical attention if symptoms occur.
    • Ingestion: Rinse mouth; do not induce vomiting; seek medical attention.
  • Waste: Collect in appropriate organic waste stream according to institutional and regulatory guidelines.
  • Special risks: Unknown. Until data are available, treat as potentially harmful and avoid heating, strong UV exposure, or oxidizing conditions.

Note: This product is designated For research use only.

Solvent Selection

No compound-specific polarity or solubility data are available in the Product Data. The following decision framework reflects common practice for small-molecule library members:

  • First-line solvent: DMSO (anhydrous) for primary stock solutions due to broad solvating power and assay compatibility at ≤0.5–1% v/v in many biochemical and cell-based assays.
  • Secondary options: DMF, NMP (use cautiously in biological systems), methanol, ethanol, isopropanol. For less polar scaffolds, consider acetone, acetonitrile, or ethyl acetate for intermediate processing (not usually for biological assays).
  • Aqueous work: Prepare concentrated stocks in DMSO and dilute into buffer while vortexing to final DMSO ≤0.1–1% v/v. Add non-ionic surfactant (e.g., 0.01–0.05% Tween-20) if allowed by assay and precipitation is observed (general practice).
  • pH leverage: If the compound is predicted to be basic or acidic, modest pH adjustments (pH 3–4 for bases; pH 8–9 for acids) can improve solubility. Verify compound stability at the adjusted pH.

Quick comparison (general):

  • DMSO: Broad solubility, good stability profile, widely accepted in screening; high boiling point.
  • DMF/NMP: Strong solvents for recalcitrant solids; more safety considerations in bioassays.
  • Alcohols (MeOH/EtOH): Useful co-solvents; often compatible with spectroscopic methods.

Always validate solubility and stability for ERD-12310A with a small pilot before scaling to plates.

Storage and Reconstitution

Item-specific storage from Product Data:

  • Storage Conditions: Store at −20 °C.
  • Shipped In: Ice chest + Ice pads.

Additional best-practice guidance (general; verify compatibility with your application):

  • Protect from moisture and excessive light until stability is known. If supplied as dry film/powder, keep tightly closed in original container with desiccant.
  • Upon receipt, equilibrate to room temperature before opening to prevent condensation.
  • Reconstitution: Start with anhydrous DMSO to prepare a concentrated stock (e.g., 10–50 mM), then aliquot into single-use portions to avoid freeze–thaw. Record exact concentration based on weight-in/volume-out and adjust for salt form if known.
  • Working solutions: Prepare fresh on the day of use when possible. If short-term storage is needed, keep at 2–8 °C protected from light; confirm stability experimentally.
  • Freeze–thaw: Minimize cycles. If repeated use is expected, create multiple small aliquots.

Item-specific stabilizers, water content, or solution stability: Not specified for this item; refer to CoA/Spec Sheet.

Note: For research use only.

Structure and Identity

Concise identifier information for ERD-12310A as supplied in a small-molecule/compound library format.

  • Item-specific identifiers (from Product Data):

    • SKU: E1448525
    • Product Name: ERD-12310A
    • CAS: Not specified for this item; refer to CoA/Spec Sheet.
    • InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
    • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Structural features: Not specified for this item; refer to CoA/Spec Sheet.

  • Notes on library compounds (general):

    • Members of screening libraries are typically drug-like small molecules adhering loosely to property guidelines (e.g., Lipinski/Ro5), but exact functional groups, ring systems, and stereochemistry vary by entry.
    • When structure is provided on the CoA/Spec Sheet, document any chiral centers, heterocycles, halogenation, and ionizable groups, as these affect solubility, storage, and assay design.
    • For 2D description (general guidance): Identify core scaffold (e.g., heteroaromatic ring), count and position of heteroatoms (N, O, S), substituent topology (para/meta/ortho for aromatics), and any cation/anion counterions if present (salts).
Synthetic Utility

The structure of ERD-12310A is not provided; thus, no specific synthetic transformations or functional-group reactivities can be assigned.

General guidance (if structural information becomes available via CoA/Spec Sheet):

  • Identify key functional handles (e.g., aryl halides for cross-coupling, amines/acids for amide formation, alcohols for esterification/etherification) to plan analog synthesis or bioconjugation.
  • Use retrosynthetic disconnections guided by the core scaffold: heteroaromatic coupling (Suzuki, Buchwald–Hartwig), reductive amination, or heterocycle construction as appropriate.
  • For salt forms or protecting groups, document counterions and protection strategy before derivatization.

Until the structure is known, ERD-12310A should be treated as a screening molecule rather than a synthetic building block.

Target Specificity

No target, pathway, or selectivity information is supplied for ERD-12310A.

  • Target/antigen: Not specified for this item; refer to CoA/Spec Sheet if available.
  • Species reactivity/assay class: Not specified for this item; refer to internal screening records.

Guidance for determination (general):

  • If ERD-12310A emerges as a hit, establish primary potency (e.g., IC50/EC50) in your assay of interest, then perform selectivity profiling across related targets and common off-target panels.
  • Use orthogonal methods (biophysical and enzymatic/cellular) to confirm direct target engagement and reduce the risk of artifacts.

Souhaitez-vous que nous vous envoyions un message lorsque des réductions seront disponibles?

Me rappeler plus tard

Merci ! Veuillez vérifier votre boîte de réception e-mail pour confirmer.

Oups ! Les notifications sont désactivées.